We are a Venture Capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus on ALS

Neurodegeneration is the leading cause of death and disability

1 in 5 people will get a neurodegenerative disease.

1 in 350 people will get ALS - as many as Multiple Sclerosis

But the tide is turning: Neurodegenerative diseases can become a managed condition

New drugs could dramatically improve quality of life within the next decade by preserving cognition and motor function

We are supporting & backing extraordinary people,

working to change the course of neurodegenerative diseases

After 10 successful years we are convinced that our joint efforts will help us accelerate the new generation of therapies